Skip to main content

Neurological symptoms in Long COVID patients persist up to three years

Effects include brain fog, fatigue and depression
brain fog
Among the most significant findings, the symptoms of ‘brain fog,’ characterized by cognitive dysfunction, was experienced by 60% of patients and fatigue was experienced by 74%.

CHICAGO --- Scientists from Northwestern Medicine and the School of Medicine at CES University and CES Clinic in Colombia have determined that more than 60% of people who had Long COVID have neurological symptoms that impact their cognitive function and quality of life, even two and three years after COVID-19.

This finding resulted from a study with the longest follow-up time conducted in Latin America and was led by Dr. Igor J. Koralnik, chief of neuro-infectious diseases and global neurology at Northwestern University Feinberg School of Medicine, and Dr. Carolina Hurtado Montoya, with the School of Medicine at CES University in Medellín. It is the first study in Colombia and Latin America to analyze persistent neurological symptoms, cognitive function and quality of life in Long COVID patients.

Between April 2023 and December 2023, researchers evaluated the long-term effects of Long COVID in a group of 100 Colombian patients, which included a group of 50 people, average age of 51, who presented moderate or severe disease and were hospitalized at the CES Clinic in Medellín. The other group of 50 patients were not hospitalized, had mild COVID-19 and were an average age of 36.

Among the most significant findings, the symptoms of ‘brain fog,’ characterized by cognitive dysfunction, was experienced by 60% of patients and fatigue was experienced by 74%. These two symptoms, along with depression, most affected their quality of life and cognitive function, in both the group of patients who required hospitalization (moderate and severe COVID-19) during the acute infection, and in people who had mild COVID-19.

“Our findings highlight the high incidence and heterogeneity of the neurologic symptoms and impacts of Long COVID even more than two years from disease onset. Early detection, emotional support and targeted management of these patients are warranted,” according to the study.

These results were published August 13 in Frontiers in Human Neuroscience. The research group is finalizing details to begin a second phase of the study, focused on cognitive rehabilitation, to improve the functionality and quality of life of these patients. From this new effort, researchers expect to adapt and test a protocol that can later be implemented as a service at the IPS Universidad CES in Sabaneta, Antioquia, Colombia.

Results

The most common neurological symptoms in patients with Long COVID were ‘brain fog’ in  60% of patients, muscle pain in 42% and numbness or tingling in 41%. Non-neurological symptoms were fatigue (74%), sleep problems (46%) and anxiety (44%).

Both patient groups also performed worse on processing speed and attention than the general population, the study reports.

“‘Brain fog’ and fatigue remained persistent regardless of the duration of Long COVID, underscoring the need for comprehensive and long-term care for those affected by this condition,” the authors wrote.

This analysis also involved medical students, physicians, neurology residents, neurologists, and researchers from CES University and CES Clinic, Diego Fernando Rojas-Gualdrón, Esteban Villegas Arbeláez, Salvador Ernesto Medina Mantilla, Mariana Campuzano-Sierra, Santiago Ospina-Patiño, Mariana Arroyave-Bustamante, Valeria Uribe-Vizcarra, Daniel Restrepo-Arbeláez, Paul Cardona, Julián Llano-Piedrahita, Santiago Vásquez-Builes, Esteban Agudelo-Quintero, Juliana Vélez-Arroyave, Sebastián Menges, as well as the team  from Northwestern University including Gina S. Pérez Giraldo, Millenia Jiménez, Janet Miller and Yina M. Quique.

This study demonstrates that the neurologic manifestations of Long COVID are as frequent in Colombia as they are in the U.S. This collaboration was initiated by Dr. Gina Perez Giraldo who went to Medical School at CES University in Medellin, and was the recipient of a Global Neurology fellowship from the Havey Institute of Global Health at Northwestern.

Notes

This analysis also involved medical students, physicians, neurology residents, neurologists, and researchers from CES University and CES Clinic, Diego Fernando Rojas-Gualdrón, Esteban Villegas Arbeláez, Salvador Ernesto Medina Mantilla, Mariana Campuzano-Sierra, Santiago Ospina-Patiño, Mariana Arroyave-Bustamante, Valeria Uribe-Vizcarra, Daniel Restrepo-Arbeláez, Paul Cardona, Julián Llano-Piedrahita, Santiago Vásquez-Builes, Esteban Agudelo-Quintero, Juliana Vélez-Arroyave, Sebastián Menges, as well as the team  from Northwestern University including Gina S. Pérez Giraldo, Millenia Jiménez, Janet Miller and Yina M. Quique.

This collaboration was initiated by Dr. Gina Perez Giraldo who went to Medical School at CES University in Medellin, and was the recipient of a Global Neurology fellowship from the Havey Institute of Global Health at Northwestern.